{"id":"nct:NCT04016129","kind":"trial","title":"CAR-T Immunotherapy Targeting CD19- ALL","authors":["Shenzhen Geno-Immune Medical Institute"],"author_count":1,"year":2019,"published":"2019-07-11","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT04016129","source_url":"https://clinicaltrials.gov/study/NCT04016129","archive_url":"https://space-kitty.com/papers/nct:NCT04016129","updated":"2026-08-26","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients developed CD19-negative disease after CD19 CART immunotherapy. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["B-cell Leukemia"],"details":{"acronym":null,"status":"NOT_YET_RECRUITING","phase":"PHASE1, PHASE2","study_type":"INTERVENTIONAL","enrollment":100,"sponsor":"Shenzhen Geno-Immune Medical Institute","conditions":["B-cell Leukemia"],"interventions":["BIOLOGICAL: 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR"],"start_date":"2027-07-01","start_date_type":"ESTIMATED","primary_completion_date":"2028-06-30","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}